Altimmune, Inc.
NASDAQAltimmune enters the back half of May with its highest-conviction clinical catalyst in years, yet short sellers have barely flinched — a striking standoff between data momentum and a deeply entrenched bear camp. Short interest commands the centre of this story. At 34.6% of the free float, it has climbed roughly 21% over the past month — the bulk of that jump arriving in a single…
Snapshot as of 27 May 2026
Altimmune enters the back half of May with its highest-conviction clinical catalyst in years, yet short sellers have barely flinched — a striking standoff between data momentum and a deeply entrenched bear camp. Short…
Altimmune just reported Q1 results, beat its EPS estimate, and simultaneously saw short sellers add aggressively — a setup that puts the stock in a genuinely unusual position heading into what comes next. The short…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for ALT — free to start on ORTEX.
Sign up for free →Open ALT on ORTEX